Antibody against RSV helps prevent wheeze in infants

BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f3089 (Published 15 May 2013)
Cite this as: BMJ 2013;346:f3089

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

OpenUrlCrossRefMedline

Palivizumab is a monoclonal antibody directed against respiratory syncytial virus (RSV) and an effective prophylactic against severe infection in high risk infants. A new trial in preterm infants reports that the drug also helps prevent …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL